Skip to main content
. 2018 Feb 26;9(21):15658–15672. doi: 10.18632/oncotarget.24585

Figure 4. Ribociclib enhances cisplatin-induced G2/M arrest.

Figure 4

Cell cycle phase diagrams after 24 h (A), 48 h (B), and 72 h (C) of treatment with cisplatin alone or concurrent 1ug/mL cisplatin and the indicated dose of Ribociclib, or no treatment. (D) Absolute cell counts in (i) COV504 and (ii) PEO cells after treatment with cisplatin followed by maintenance Ribociclib. (E) Absolute cell counts in (i) COV504 and (ii) PEO cells after concurrent treatment with cisplatin and Ribociclib without maintenance Ribociclib. (F) Absolute cell counts in (i) COV504 and (ii) PEO1 cells after concurrent treatment with cisplatin and Ribociclib followed by maintenance Ribociclib. All samples were analyzed in triplicate with each experiment replicated at least once. *p < 0.05, **p < 0.01, ***p < 0.001 by two-sided, two-tailed t-tests.